SG Americas Securities LLC acquired a new position in Crispr Therapeutics AG (NASDAQ:CRSP) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,504 shares of the company’s stock, valued at approximately $758,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Nikko Asset Management Americas Inc. boosted its stake in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares in the last quarter. ARK Investment Management LLC lifted its stake in shares of Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the period. Wells Fargo & Company MN grew its stake in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Morgan Stanley raised its holdings in Crispr Therapeutics by 6.1% in the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after acquiring an additional 16,361 shares during the period. 49.81% of the stock is owned by institutional investors.
CRSP has been the topic of a number of recent analyst reports. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday. TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Finally, Chardan Capital restated a “buy” rating and issued a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $69.54.
CRSP opened at $72.37 on Friday. The company has a market cap of $3.95 billion, a price-to-earnings ratio of -21.04 and a beta of 3.30. The firm has a 50 day simple moving average of $54.81 and a 200 day simple moving average of $47.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. Crispr Therapeutics AG has a fifty-two week low of $22.22 and a fifty-two week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. As a group, analysts expect that Crispr Therapeutics AG will post 0.65 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 in the last 90 days. Company insiders own 21.40% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Trading on Margin
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.